PREDICTION OF LATE BREAST CANCER RECURRENCE BY THE ROR (PAM50) SCORE IN POSTMENOPAUSAL WOMEN IN THE TRANSATAC COHORT

被引：0
|
作者：
Cuzick, J. [1 ]
Sestak, I. [1 ]
Ferree, S. [2 ]
Cowens, J. W. [2 ]
Dowsett, M. [3 ]
机构：
[1] Queen Mary Univ London, Ctr Epidemiol Math & Stat, London, England
[2] NanoString Technol, Nanostring Technol, Seattle, WA USA
[3] Breakthrough Res Ctr, Acad Dept Biochem, London, England
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：75 / 76
页数：2
相关论文
共 50 条
  • [41] Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study
    Troester, Melissa A.
    Sun, Xuezheng
    Allott, Emma H.
    Geradts, Joseph
    Cohen, Stephanie M.
    Tse, Chiu-Kit
    Kirk, Erin L.
    Thorne, Leigh B.
    Mathews, Michelle
    Li, Yan
    Hu, Zhiyuan
    Robinson, Whitney R.
    Hoadley, Katherine A.
    Olopade, Olufunmilayo I.
    Reeder-Hayes, Katherine E.
    Earp, H. Shelton
    Olshan, Andrew F.
    Carey, Lisa A.
    Perou, Charles M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (02):
  • [42] PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
    Jorgensen, Charlotte L. T.
    Nielsen, Torsten O.
    Bjerre, Karsten D.
    Liu, Shuzhen
    Wallden, Brett
    Balslev, Eva
    Nielsen, Dorte L.
    Ejlertsen, Bent
    ACTA ONCOLOGICA, 2014, 53 (06) : 776 - 787
  • [43] Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Ohnstad, Hege O.
    Borgen, Elin
    Falk, Ragnhild S.
    Lien, Tonje G.
    Aaserud, Marit
    Sveli, My Anh T.
    Kyte, Jon A.
    Kristensen, Vessela N.
    Geitvik, Gry A.
    Schlichting, Ellen
    Wist, Erik A.
    Sorlie, Therese
    Russnes, Hege G.
    Naume, Bjorn
    BREAST CANCER RESEARCH, 2017, 19
  • [44] Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Hege O. Ohnstad
    Elin Borgen
    Ragnhild S. Falk
    Tonje G. Lien
    Marit Aaserud
    My Anh T. Sveli
    Jon A. Kyte
    Vessela N. Kristensen
    Gry A. Geitvik
    Ellen Schlichting
    Erik A. Wist
    Therese Sørlie
    Hege G. Russnes
    Bjørn Naume
    Breast Cancer Research, 19
  • [45] Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor-Positive Breast Cancer
    Kelly, Catherine M.
    Bernard, Philip S.
    Krishnamurthy, Savitri
    Wang, Bailiang
    Ebbert, Mark T. W.
    Bastien, Roy R. L.
    Boucher, Kenneth M.
    Young, Elliana
    Iwamoto, Takayuki
    Pusztai, Lajos
    ONCOLOGIST, 2012, 17 (04): : 492 - 498
  • [46] Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR plus ), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)
    Eriksen, J. Ole
    Jensen, M-B
    Laenkholm, A-V
    Kiboll, T.
    Rasmussen, B. Bruun
    Knoop, A. S.
    Ferree, S.
    Haffner, T.
    Buckingham, W.
    Schaper, C.
    Ejlertsen, B.
    CANCER RESEARCH, 2016, 76
  • [47] Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)
    Ma, Cynthia X.
    Anurag, Meenakshi
    Dockter, Travis
    Hoog, Jeremy
    Fernandez-Martinez, Aranzazu
    Fan, Cheng
    Gibbs, Richard
    Sanati, Souzan
    Vij, Kiran
    Watson, Mark
    Hahn, Olwen
    Guenther, Joseph
    Caudle, Abigail
    Crouch, Erika
    Tiersten, Amy
    Mita, Monica
    Razaq, Wajeeha
    Hieken, Tina J.
    Wang, Yang
    Leitch, A. Marilyn
    Unzeitig, Gary W.
    Weiss, Anna
    Winer, Eric P.
    Hunt, Kelly
    Partridge, Ann H.
    Carey, Lisa A.
    Perou, Charles M.
    Ellis, Matthew J.
    Suman, Vera
    CANCER RESEARCH, 2022, 82 (04)
  • [48] Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
    Sestak, Ivana
    Cuzick, Jack
    Dowsett, Mitch
    Lopez-Knowles, Elena
    Filipits, Martin
    Dubsky, Peter
    Cowens, John Wayne
    Ferree, Sean
    Schaper, Carl
    Fesl, Christian
    Gnant, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) : 916 - +
  • [49] Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohort
    Sanchez Bayona, R.
    Tolosa, P.
    Alba Bianchi, M.
    Madariaga Urrutia, A.
    Teran, S.
    Rey Cardenas, M.
    Lema Roso, L.
    Ruano, Y.
    Manso, L.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2022, 33 : S143 - S144
  • [50] Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes
    Santonja, Angela
    Sanchez-Munoz, Alfonso
    Fernandez, Yessica Plata
    Miramon, Jose
    Zarcos, Irene
    Perez, Casilda Llacer
    de Luque, Vanessa
    Fernandez-Sousa, Cristina
    Jerez, Jose Manuel
    Alvarez, Martina
    Vicioso, Luis
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345